Recent News

• 04.22.2025 - Paysign to Host First Quarter 2025 Earnings Call
• 04.21.2025 - Paysign is a Sponsor at the 2025 International Plasma Protein Therapeutics Conference, Warsaw, Poland
• 04.09.2025 - Paysign, Inc. to Present at the Ladenburg Thalmann Technology Innovation EXPO25
• 04.04.2025 - Paysign is a Sponsor at the 2025 Innovative Payments Conference, Washington, D.C.
• 04.01.2025 - Paysign is a Supporting Sponsor at the Pharmaceutical Compliance Congress 2025, McLean, VA
• 03.25.2025 - Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results
• 03.25.2025 - Paysign, Inc. Announces Acquisition of Gamma Innovation’s Assets, Appoints Michael Ngo as Chief Innovation Officer
• 03.05.2025 - Paysign to Attend Asembia Specialty Pharmacy Summit, April 27-May 01, 2025
• 02.27.2025 - Paysign to Host Fourth Quarter and Full Year 2024 Earnings Call
• 02.26.2025 - Paysign is a Sponsor at ACCESS USA 2025, March 18-20, Philadelphia, PA

Recent Filings

• 03.27.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.27.2025 - DEF 14A Other definitive proxy statements
• 03.26.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 4 Statement of changes in beneficial ownership of securities